磁共振弥散加权成像对原发性肝癌的诊断及索拉非尼治疗效果

Imaging Diagnosis of Primary Liver Cancer Using Magnetic Resonance Dilated Weighted Imaging and the Treatment Effect of Sorafenib.

机构信息

General Surgery, The First Affiliated Hospital of Northwest University (Xi'an No. 1 Hospital), Xi'an, 710000 Shaanxi, China.

Public Health and Management Department, Ningxia Medical University, Yinchuan, 750001 Ningxia, China.

出版信息

Comput Math Methods Med. 2022 Jun 28;2022:8586943. doi: 10.1155/2022/8586943. eCollection 2022.

DOI:10.1155/2022/8586943

PMID:35799672

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9256338/

Abstract

OBJECTIVE

This work explores the application value of dilated weighted imaging (DWI) in the diagnosis of primary liver cancer (PLC) and the effect of sorafenib in the treatment of PLC.

METHODS

88 patients with PLC who were treated in The First Affiliated Hospital of Northwest University from March 2019 to March 2021 were selected and randomly rolled into an experimental group and a control group, with 44 cases in each group. Patients in both groups were treated with transcatheter arterial chemoembolization (TACE), and the patients in the experimental group were treated with oral sorafenib on the basis of TACE. The indicators of complications, short-term efficacy (STE), and long-term efficacy (LTE) of the two groups were observed. All patients received DWI and magnetic resonance (MR) plain scan. The diagnostic accuracy and misdiagnosis rate of the two methods in diagnosing the PLC were compared.

RESULTS

The accuracy, specificity, and sensitivity of MR plain scan were 68%, 88%, and 89%, respectively, while those of DWI were 96%, 95%, and 94.2%, respectively. It indicated that the accuracy, specificity, and sensitivity of DWI in diagnosing lesions were better than those of MR plain scan, especially the diagnostic accuracy ( < 0.05). The objective response rate (ORR) and disease control rate (DCR) of the STE in the experimental group were 30% and 97%, respectively, and those in the control group were 6% and 54.5%, respectively. The experimental group's mean progression-free survival (mPFS) and mean overall survival (mOS) were 12 and 25 months, respectively, while the control group's were 8 and 19 months, respectively. It was concluded that the mPFS and mOS of patients receiving TACE combined with oral sorafenib were much higher than those receiving TACE only ( < 0.05).

CONCLUSION

DWI and TACE combined with sorafenib had high application value in the diagnosis and treatment of PLC.

摘要

目的

本研究旨在探讨弥散加权成像（DWI）在原发性肝癌（PLC）诊断中的应用价值及索拉非尼治疗 PLC 的效果。

方法

选取 2019 年 3 月至 2021 年 3 月在西北大学第一附属医院治疗的 88 例 PLC 患者，采用随机数字表法分为实验组和对照组，每组 44 例。两组患者均采用经导管肝动脉化疗栓塞术（TACE）治疗，实验组患者在 TACE 治疗的基础上口服索拉非尼。观察两组患者的并发症指标、短期疗效（STE）和长期疗效（LTE）。所有患者均接受 DWI 和磁共振（MR）平扫检查。比较两种方法诊断 PLC 的准确率和误诊率。

结果

MR 平扫的准确率、特异度和敏感度分别为 68%、88%和 89%，DWI 分别为 96%、95%和 94.2%。提示 DWI 诊断病变的准确率、特异度和敏感度均优于 MR 平扫，尤其是诊断准确率（<0.05）。实验组 STE 的客观缓解率（ORR）和疾病控制率（DCR）分别为 30%和 97%，对照组分别为 6%和 54.5%。实验组的中位无进展生存期（mPFS）和中位总生存期（mOS）分别为 12 个月和 25 个月，对照组分别为 8 个月和 19 个月。结果表明，接受 TACE 联合口服索拉非尼治疗的患者 mPFS 和 mOS 明显高于接受单纯 TACE 治疗的患者（<0.05）。